CellsBin Inc.

Based in the US, CellsBin Inc. , operates as a provider of rare-cell detection and clinical insight solutions using photonics, AI, and translational science. Founded in 2023, CellsBin Inc. is based in the US and specializes in rare-cell detection technologies.

CellsBin® specializes in pioneering Rare-Cell Biology™, offering advanced diagnostic solutions designed to detect and analyze rare therapeutic cells critical to improving patient outcomes. Their flagship products include CellsBin Scout™, CellsBin Insight™, and CellsBin Polaris™, which leverage ultrasensitive detection capabilities and single-cell profiling to address challenges across the healthcare spectrum. CellsBin Scout™ facilitates the identification and quantification of rare therapeutic cells in blood circulation, supporting various stages from initial clinical studies to long-term patient management. CellsBin Insight™ aims to enhance blood-based assessment of multiple myeloma through sensitive disease detection and monitoring, while CellsBin Polaris™ integrates patented detection technologies with AI and biological monitoring to enable actionable insights for precision medicine.

These products serve a diverse client base, primarily comprising biomedical researchers, biopharmaceutical companies, and clinical laboratories, with a focus on markets in North America and Europe. CellsBin® operates within a specialized revenue framework centered on collaborations with biopharma and clinical partners for the provision of its innovative products and services. Transactions typically occur through subscription models and partnerships, enabling continuous engagement and support for research and clinical applications. The company’s offerings, such as CellsBin Scout™, CellsBin Insight™, and CellsBin Polaris™, cater to institutional clients that require high-throughput capabilities for rare-cell analysis and monitoring.

Pricing structures vary based on the scope of the partnership and specific product utilization, reflecting the tailored nature of the solutions provided. Additionally, these strategic alliances foster ongoing development within clinical and translational research, emphasizing the importance of CellsBin's role in advancing precision medicine through comprehensive data and insights. The company plans to use the funding raised in September 2026 to expand products, partnerships, and clinical capabilities.